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Abstract
Breast cancer is among the lethal types of cancer with a high mortality rate, globally. Its
high prevalence can be controlled through improved analysis and identification of
disease‐specific biomarkers. Recently, long non‐coding RNAs (lncRNAs) have been reported as key contributors of carcinogenesis and regulate various cellular pathways
through post‐transcriptional regulatory mechanisms. The specific aim of this study was to
identify the novel interactions of aberrantly expressed genetic components in breast
cancer by applying integrative analysis of publicly available expression profiles of both
lncRNAs and mRNAs. Differential expression patterns were identified by comparing the
breast cancer expression profiles of samples with controls. Significant co‐expression
networks were identified through WGCNA analysis. WGCNA is a systems biology
approach used to elucidate the pattern of correlation between genes across microarray
samples. It is also used to identify the highly correlated modules. The results obtained
from this study revealed significantly differentially expressed and co‐expressed lncRNAs
and their cis‐ and trans‐regulating mRNA targets which include RP11‐108F13.2 targeting
TAF5L, RPL23AP2 targeting CYP4F3, CYP4F8 and AL022324.2 targeting LRP5L,
AL022324.3, and Z99916.3, respectively. Moreover, pathway analysis revealed the
involvement of identified mRNAs and lncRNAs in major cell signalling pathways, and
target mRNAs expression is also validated through cohort data. Thus, the identified
lncRNAs and their target mRNAs represent novel biomarkers that could serve as potential therapeutics for breast cancer and their roles could also be further validated
through wet labs to employ them as potential therapeutic targets in future.

1 | INTRODUCTION
Breast cancer (BC) is a genetically diverse disease and one of
the major types of cancer. Based on statistical facts,
approximately 1,675,000 women are affected by BC every
year with a mortality rate of 500,000 [1]. One of the major
reasons behind the prevalence of BC is its poor prognosis
due to the high diversity demonstrated in its pathological
features and behaviours [2]. Clinically, breast cancer is divided
into four main molecular subtypes, Luminal‐A, Luminal‐B,
HER2‐Positive and Triple negative breast cancer [3]. These

subtypes are based on the hormonal and growth receptors
that is oestrogen receptor (ER), progesterone receptor (PR)
and human epidermal growth factor receptor2 (HER2)
regulating cell growth signalling [2, 4]. Keeping in mind the
pathogenic effects of this disease, there is a sheer need to
identify novel therapeutic targets to combat BC [5]. Various
studies provide evidence about the abnormal expression of
lncRNA genes in breast tumours [6, 7]. They play an
important role in regulating cancer pathways [8]. The size of
lncRNAs is approximately greater than 200 nucleotides and
they are the major regulators of numerous biological mech-
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anisms, that is embryonic stem cell pluripotency, cell‐cycle
regulation, different cellular pathways, gene expression regulation, transcription and post‐transcriptional regulation which
have been found to be altered in various cancers. They
regulate the transcription of protein coding genes by acting in
a cis‐ and trans‐manner [9, 10]. lncRNAs also exist as antisense transcripts in nature, affect the mRNA processing by
influencing editing of pre‐mRNA and interrupt or inhibit
mRNA splicing events, which results in affected or no proteins at all [11, 12]. They determine the total number of
proteins produced by mRNA through regulation of post‐
transcription activities. They also influence mRNA stability
in both positive and negative manners [13, 14].
Various studies have reported the overexpression of
lncRNAs in some breast cancer tissues [6, 9]. Based on their
functions and expression patterns in tumour tissues, they
can behave as oncogenes or tumour suppressor genes [15].
These studies have demonstrated the role of lncRNAs in
mediating the aetiology of BC. [16]. This necessitates a
systematic investigation to discover novel lncRNAs, along
with their target mRNAs to aid the identification of novel
biomarkers and potential therapeutic targets for BC [5].
Despite the major progress in lncRNAs discovery, they still
lack in their annotation and functional characterisation
[17, 18]. So it is essential to fill this gap through increased
analysis and discovery of lncRNAs in various diseases. New
workflows and methods in genomics research have paved
the way for conducting systems wide analysis at different
levels of diseases. Moreover, analysing lncRNAs which are
both differentially expressed and co‐expressed will assist in
discovering the genetic causes responsible for a particular
disease [19] and co‐expression will provide significant biomarkers and therapeutic targets by integrating the significant
gene expression correlation and their clinical outcome
[7, 20]. Such an analysis will increase the functional
importance of lncRNAs and will help in using them as
diagnostic and therapeutic targets in future.
In this study, integrated statistical analysis was conducted
on the expression profiles of lncRNA and mRNA data of
breast cancer patients and normal samples. Differential
expression (DE) analysis and co‐expression network analysis
have been performed on these samples. A subset of both these
datasets that can serve as significant biomarkers were obtained
from the results. These biomarkers were then subjected to
target identification to discover the novel lncRNA‐mRNA
interaction that can further help in the retrieval of therapeutic targets. Their role in breast cancer was further confirmed
through pathway analysis.

2 | MATERIALS AND METHODS
This study utilised BC samples to perform differential
expression analysis of lncRNAs of microarray expression data
and mRNA from RNA‐seq data. Co‐expression network
analysis and pathway analysis of both samples were also
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performed. Moreover, integrated analysis was performed to
identify the targets of lncRNAs in mRNA samples. The overall
methodology of this study is shown in Figure 1.

2.1 | Dataset selection
Dataset selection was based on experiments from human
origin excluding the cell lines and samples which contain any
mutations, drug and specific gene‐ or protein‐induced effects.
Moreover, two datasets from both microarray and RNA‐Seq
platforms were selected. These datasets contain an appropriate number of samples for both breast cancer patients and
control group to generate a statistically significant analysis.

2.2 | Microarray expression data
The quantile normalised series matrix file of the publicly
available lncRNA microarray dataset GSE80266 was obtained
from the GEO database. The genetic chip, which was processed by in situ oligonucleotide technology, comprised the
GPL15314 Arraystar Human lncRNA microarray V2.0,
(Agilent_033,010 Probe Name version). It contains a total of
10 samples including 5 breast cancer samples and 5 from the
control group. The quality of data was assessed through the
box plot and MA plot. Moreover, lncRNA analysis was
performed on two other publicly available datasets of
microarray platforms from the GEO database with accession
numbers GSE113851 and GSE119233, respectively. The
dataset GSE113851 comprised a chip with spotted oligonucleotide technology and the GPL16847 Invitrogen NCode
Human Non‐coding RNA Microarray (NCRAH‐02) platform. Its sample size was 57 including 44 breast cancer and
13 normal breast samples. GSE119233 consists of in situ
oligonucleotide technology with GPL16956 Agilent‐045,997
Arraystar human lncRNA microarray V3 (Probe Name
Version). It contains 30 samples including 10 normal and 20
breast cancer samples.

2.3 | Re‐annotation and differential
expression analysis of lncRNAs
The series matrix file of dataset GSE80266 represented the
expression levels of probes with the probe IDs. To find the
respective genes, re‐annotation was performed for the retrieval
of the corresponding Ensemble IDs. For this purpose, the
probe sequences were mapped to human reference genome
hg38 using TOPHat [21], and converted to an identifiable
browser extensible format (BED) utilising BED tools [22]. The
probes with a mapping score of 50 were considered significant.
A coding potential assessment tool (CPAT) [23] was used to
filter the coding and non‐coding sequences.The non‐coding
sequences were subjected to the Biomart package of R software for accessing their Ensemble IDs and gene names.
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F I G U R E 1 Overall Workflow of Methodology. Microarray and RNA‐Seq datasets were retrieved from the Gene Expression Omnibus (GEO) database.
The total number of samples in microarray datasets were 10, whereas, RNA‐Seq data comprised 20 samples. Furthermore, microarray and RNA‐Seq data
analysis was performed for the identification of differentially expressed lncRNAs. After that, co‐expression network analysis was performed on both datasets and
common lncRNAs were selected from both types of analyses that is, DE analysis and co‐expression network analysis. Targets for the selected lncRNAs were
found and merged with the mRNA subsets for retrieving common biomarker genes in breast cancer in integrated analysis

The difference in expression levels was measured by
comparing the control with the case samples, applying the
Student’s t‐test along with a multiple test correction method by
Benjamini‐Hochberg [24]. The decision rule for selecting
differentially expressed lncRNA genes was based on both
p‐value and adjusted p‐value less than 0.05. The filtered
non‐coding probes and lncRNA DEGs are given in the
supplementary file 1.
For both datasets used for validation, DEG analysis was
performed on series matrix files. The quality assessment
was performed using box plots and log2 transformation [25]
was applied for normalisation. DE analysis was performed
using limma [26] and re‐annotation of the DEGs for dataset
GSE119233 was retrieved from BLAT [27], while annotation
for GSE113851 was already provided with the dataset.

(6 = triple negative, 6 = non‐triple negative, 5 = HER2 positive) and 3 control samples. The paired end raw data files were
retrieved in FATSQ format. The quality of data was assessed
using FASTQC tool [31] and technical errors were preprocessed using Trimmomatic [32]. For preprocessing, ILLUMINACLIP,
SLIDINGWINDOW,
LEADING
and
TRAILING were used with their default settings. HEADCROP, which removes a specific number of bases from the
start of read, was given the value 15 for the removal of
contaminated bases in the data, and MINLEN which removes
the read if it falls off a threshold length was given the value of
36 [32]. After preprocessing, errors were removed from the
data. The preprocessed sequences were mapped to the human
reference genome hg38 with Bowtie [33]. These mapped sequences were analysed using featureCounts tool. This whole
analysis was performed employing a pipeline of tools built on
the galaxy platform [34].

2.4 | RNA‐seq analysis
Transcriptome studies on eukaryotes have been upgraded with
the advancements in next‐generation sequencing technologies
[28]. RNA‐sequencing is one of the important NGS techniques
used in transcriptome analysis, which have exceeded the
microarray technologies, as they use highly parallel methods
that are less time consuming and more predictive [29]. It has
great importance in the identification of gene expression
profiles, novel gene discovery, finding alternative variants,
transcripts and allele specific expressions, etc. and has provided
an unlimited knowledge based on these studies [30].
The publicly available RNA‐Seq dataset GSE52194 processed form Illumina HiSeq was obtained from GEO, containing 17 breast cancer samples with three different subtypes

2.5 | Differential expression analysis of
mRNA data
Three different R tools, that is DESeq [19], edgeR [35] and
limma‐voom [26] were utilised for determining the differential
expression of mRNA read counts to acquire the best results
with significant p‐value and the false discovery rate (FDR) of
threshold <0.05. For DE analysis, the read counts with low
expression values were removed. Genes with the minimum 1
counts per million (cpm) in at least two samples were kept for
further analysis. The read counts were normalised through
trimmed mean of M values (TMM) normalisation, applied by
the edgeR and limma‐voom in R, while DESeq, applied

140

-

median of ratios for normalisation of the counts. Filtered
expression matrix for DE analysis of mRNA is provided in
supplementary file 2.
For assuring the significance of analysis and differential
expressions of target mRNA genes in BC, another DEGs
analysis was performed on two publicly available mRNA
datasets from GEO database with microarray platforms having
accession numbers GSE22820 and GSE26910, respectively.
The genetic chip of GSE22820 was processed by in situ
oligonucleotide technology and comprised GPL6480 Agilent‐
014,850 Whole Human Genome Microarray 4 � 44 K
G4112 F (Probe Name version). Its sample size was 186
including 10 samples from control group and 176 from primary breast cancer patients. Moreover, the dataset GSE26910
consists of in situ oligonucleotide chip with GPL570 [HG‐
U133‐Plus‐2] Affymetrix Human Genome U133 Plus 2.0
Array. It consists of a total of 24 samples, including 6 control
and 6 breast cancer samples along with 6 samples from control
group and 6 prostate cancer samples; from this whole dataset,
only 12 samples with BC patients along with their respective
controls were used for performing DE analysis.
Differential expression analysis of both datasets was performed on their series matrix files. The quality of data was
observed using box plots. For normalisation, log2 transformation [25] was performed on both datasets and significantly differentially expressed genes were retrieved using limma
[26] from R Bioconductor package.

2.6 | Analysis of Co‐expression networks
The co‐expression network analysis facilitates in finding the
clusters of highly correlated or co‐expressed gene expression
profiles and helps to determine the candidate biomarkers and
potential therapeutic targets of various diseases including
cancer. This analysis was performed using WGCNA package
[20] in R, to acquire the novel biomarkers that could act as
breast cancer therapeutics as it provides the cluster of hub
genes involved in similar disease pathways [20]. Quantile normalised microarray data and RNA‐Seq data with vst and
quantile normalisation was utilised for analysis. An initial unsupervised hierarchical clustering revealed no outliers in both
types of data. The soft threshold used for microarray data was
6 and that for RNA‐Seq data was 9. An unsigned network was
built on the basis of Pearson correlation with p‐value <0.05 for
significantly correlated modules. The threshold for minimum
module size was 30 and module membership was built for
analysis of significant genes highly correlated with breast
cancer.

2.7 | Identifying lncRNA‐mRNA
interactions
For the retrieval of lncRNA‐mRNA interactions, common
lncRNAs were selected from both differential expression
analysis and WGCNA analysis. For verifying the
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chromosomal locations of selected genes, an alignment tool
Blat was used [27]. Those positions were further used to
retrieve the gene IDs and names from BioMart along with
their upstream and downstream target genes. Moreover, R‐
code was developed, considering the cis‐ and trans‐activity
of lncRNA, for retrieving the target genes from selected
lncRNAs. It was based on the assumption that the cis‐ and
trans‐lncRNA target genes are located within the locality of
10‐300 kb away from lncRNAs in the upstream or downstream region, respectively [36]. After the retrieval of lncRNA
target genes, they were merged with mRNA genes in R. A
subset of common genes retrieved after merging were
determined as differentially expressed biomarker mRNA
genes. Their role in breast cancer was also confirmed through
pathway analysis using different databases including KEGG
[37], PathCards [38] and literature search.

2.8 | TCGA of mRNA
To verify the involvement of mRNA targets of lncRNAs in
breast cancer, TCGA cohort was performed using Bioconductor R package (TCGAbiolinks) [39]. The total 140
breast cancer primary tumour samples and 113 normal breast
tissues samples were retrieved from TCGA database. The
quantile normalisation was performed on data and then
mRNA differential expression analysis was preformed utilising
Bioconductor egdeR [35]. Then Log2FC values of target
mRNAs were analysed.
The http://gepia.cancer‐pku.cn/GEPIA (http://gepia.
cancer‐pku.cn/) tool was also used to validate the expression
of mRNA targets in breast cancer. A total of 1085 tumour
samples and 291 normal were analysed. LIMMA method for
differential expression analysis was employed to determine the
expression values.

3 | RESULTS
3.1 | Quality analysis of microarray data
Box plot and MA plots were plotted to analyse the quality of
quantile normalised microarray data. The overall quality of data
was good and plots revealed that data does not contain any
outliers.

3.2 | Identification of differentially
expressed lncRNAs
The total number of probes was 34,576 and they were reduced
to 30,627, after filtering on the basis of mapping score. These
probes were then passed through a tool, CPAT, which gave
29,797 non‐coding RNAs and 830 mRNAs. These 29,797,
non‐coding probes were employed for further analysis. By
applying t‐test, 181 significantly differentially expressed
lncRNA genes were obtainedand selected on the basis of
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p‐value and adjusted p‐value <0.05. Supplementary file 3
provides the lncrna DEGs.
A total 14,482 DEGs were retrieved from lncRNA dataset
GSE113851 and 8400 DEGs were provided by GSE119233.
After detailed analysis of the results from both of the lncRNA
datasets, it was observed that they did not provide the exact
locations of the lncRNAs discovered in this study. The major
reason is that the dataset GSE80266 used in analysiscomprised
novel long non‐coding RNAs in breast cancer and the data was
without any specific conditions and its re‐annotation was
carried out on the criteria of selecting the sequence with the
highest scoring. Moreover, annotations for one of the datasets
used for validation GSE113851 were provided already and the
other dataset GSE119233 was from Basal‐like Breast Cancer,
while we were focusing on the generalised BC dataset.

-

141

F I G U R E 2 Venn diagram for the Comparison of DESeq, edgeR and
limma‐voom on the Basis of p‐value. It shows the total number of
significant genes observed from each tool based on p‐value < 0.05. No
significant differentially expressed genes (DEGs) were obtained from
DESeq. EdgeR. It gave five significant DEGs based on p‐value and limma‐
voom provided 14,762 significant differentially expressed genes on the basis
of both p‐value and adjusted p‐value. There was 1 common DEG between
edgeR and limma‐voom

3.3 | Examining differentially expressed
mRNA
The preprocessed and normalised read counts were analysed
for differential expression analysis using three different tools in
R that is, DESeq, edgeR and limma‐voom. DESeq when tested
on first subtype that is Triple negative breast cancer did not
give the significant p‐value and adjusted p‐value, that is <0.05
for a single gene count due to which its results were not
considered. Moreover, edgeR gave few DEGs with significant
p‐value. But when the false discovery rate (FDR) correction
was applied on edgeR, it did not provide any significant results
on the basis of p‐adjusted value. After that, limma‐voom was
applied and it outperformed in providing significant results for
a large number of gene counts on the basis of both p‐value and
adjusted p‐value less than 0.05. So it was used further for all
the subtypes of breast cancer. The overall comparison of these
tools on the basis of p‐value is shown in Figure 2.
These results were in accordance with a study which reported that limma‐voom provides better results under different
conditions, which remains least affected by outliers, works
faster computationally and requires at least three samples to
perform the analysis [40]. The total number of significant
DEGs obtained for TNBC subtype was 7113 with upregulation, 2 DEGs were from non‐TNBC with down regulation and
16,988 DEGs were from HER2 positive subtype including
16,882 upregulated and 106 downregulated genes. Significant
DEGs of the three subtypes of BC is provided in supplementary files 4, 5 and 6, respectively.
Moreover, the datasets used for validation of analysis
provided a total of 17,423 DEGs which were obtained from
GSE22820 and 25,000 DEGs were retrieved from GSE26910.

3.4 | Co‐expression analysis using WGCNA
The co‐expression network analysis when executed on
microarray data of which built a cluster dendrogram based on
unsupervised hierarchical clustering method, illustrated in
Figure 3.

F I G U R E 3 Cluster Dendrogram of lncRNA modules dataset
GSE80266. The branches of the clusters represent modules with correlated
genes, distinguished from each other on the basis of different colours

A module‐trait relationship built with traits, that is breast
cancer and normal, provided 39 modules in total on the basis
of significant correlation approaching to ±1 and a threshold
p‐value <0.05. The modules are shown with their correlation
and p‐values in the Figure 4.
Two modules MEcyan and MEmidnight blue showed a
significant correlation of 85% and 83% along with p‐values
0.002 and 0.003, respectively. Furthermore, MEcyan module
comprised 376 total genes out of which 127 were significantly
correlated with breast cancer and MEmidnight blue included
193 lncRNA genes with 140 genes having a significant correlation with cancer. Therefore, a total of 267 lncRNAs obtained
from WGCNA were significantly correlated with cancer. Particulars for all modules from WGCNA analysis of lncRNA are
given in supplementary file 7.
Moreover, WGCNA analysis was also performed on two
more lncRNA datasets GSE113851 and GSE119233 from the
microarray platform. The cluster dendograms for both the
datasets are illustrated in supplementary Figures 6 and 8.
Moreover, two traits that is breast cancer and normal were
used to built a module‐trait relationship for both datasets. For
dataset GSE113851, the module‐trait relationship provided a
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F I G U R E 5 Cluster Dendrogram of mRNA modules dataset
GSE52194. Branches of the dendrogram correspond to modules with
correlated genes represented by different colours

F I G U R E 6 Module‐Trait relationship of mRNA modules dataset
GSE52194. The heat map shows a total of five modules, generated by
applying the correlation with external traits, that is cancer and normal.
Moreover, MEblue was the only module shown in dark red colour to hold a
56% correlation with a least p‐value of 0.01

F I G U R E 4 Module‐Trait relationship of lncRNAs dataset GSE80266.
There are 39 modules, each represented with a colour name along with their
correlation and p‐values. Modules with dark red colour in the heat map,
that is MEcyan and MEmidnight blue show a high correlation of 85% and
83% along with their significant p‐values 0.002 and 0.003, respectively

total of 75 modules based on significant correlation
approaching to ±1 and a threshold p‐value <0.05. The modules along with their correlation and p‐values are shown
graphically in the supplementary Figure 7.
The module MEblue showed a high correlation with a
significant p‐value and includes 3529 genes significantly
correlated with breast cancer. The details of its WGCNA
analysis are given in supplementary file 8.
For dataset GSE119233, a total of 14 modules were
retrieved through module‐trait relationship based on significant correlation approaching ±1 and a threshold p‐
value <0.05. The modules along with their correlation and
p‐values are shown graphically in the supplementary Figure 9.

The module MEblue includes 235 genes significantly
correlated with breast cancer.The particulars of its WGCNA
analysis are given in supplementary file 9.
For mRNA data from RNA‐Seq analysis, the cluster
dendrogram built is represented graphically in Figure 5. The
module‐trait relationship gave 5 modules and only one module
showed a significant correlation with a p‐value <0.05. The heat
map built for visualising this relationship is shown in Figure 6.
The MEblue provided maximum correlation of 56% with a
least p‐value of 0.01. There were 339 genes in this module out
of which 138 showed significant correlation with breast cancer
(Supplementary File 10).
WGCNA analysis was also performed on two mRNA
datasets GSE22820 and GSE26910 from the microarray platform for observing the co‐expression networks. For mRNA
datasets GSE22820 and GSE26910, the cluster dendograms
built are represented in supplementary Figures 10 and 12.
The module‐trait relationship for GSE22820 gave 15
modules and only one module that is MEmagenta showed a
significant correlation of 58% with a least p‐value 2e −18.
There were 71 genes in this module significantly correlated
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F I G U R E 7 Overall Representation of Integrative analysis. Yellow
coloured boxes represent lncRNAs and pink coloured boxes represent their
cis‐ and trans‐regulating mRNA targets. Red coloured lines with heads
represent targets whereas arrows represent the constituent of the relevant
signalling pathways. The lncRNA RP11‐108F13.2, based on analysis, targets
mRNA gene TAF5L, which regulates basal transcription factors pigment
epithelium‐derived factor induced signalling and the GPCR) pathway,
RPL23AP2 was found to target CYP4F3, CYP4F8 genes which regulate
and Arachidonic acid(AA) metabolism and lncRNA AL022324.2 was
observed to target LRP5L, AL022324.3 and Z99916.3, respectively Among
them LRP5L acts in the regulation of the Wnt signalling pathway and the
breast cancer pathway. While AL022324.3 and Z99916.3 were found as
breast cancer targets, their complete annotation was not found. GPCR, G‐
protein coupled receptorPathway analysis through different databases such
as PathCards [38], KEGG [37] and literature search of the genes retrieved
through integrative analysis was performed. A brief illustration of the
pathways regulated by target genes is shown in Figure 8

with breast cancer. The modules along with their p‐values and
correlation are depicted in a heat map in supplementary
Figure 11.
Moreover, the heat map of the module trait relationship of
GSE26910 is illustrated in the supplementary Figure 13. The
module MEmagenta and MEred showed a highest correlation
of 90% each with significant p‐values of 6e‐05 and 7e‐05,
respectively. MEmagenta includes 415 genes and MEred
comprises 632 genes significantly correlated with BC. The
particulars of WGCNA analysis for both datasets that is
GSE22820 and GSE26910 are given in supplementary files 11
and 12, respectively.

3.5 | Integrative analysis
The integrative analysis was carried out after retrieving
lncRNA and mRNA genes from WGCNA and DEGs analysis.
A subset of three common lncRNAs including AL022324.2,
RPL23AP2 and RP11‐108F13.2 was obtained from the whole
analysis, their cis‐ and trans‐regulating targets were acquired
using the R code from Biomart package. The lncRNA targets
retrieved, were merged with the subsets of common mRNA
genes which were also significantly differentially expressed and
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co‐expressed. A total of six common targets were identified in
mRNA subsets, including TATA‐Box Binding Protein Associated Factor 5 Like (TAF5L), Cytochrome P450 Family 4
Subfamily F Member 3 (CYP4F3), LDL Receptor Related
Protein 5 Like (LRP5L), AL022324.3, Z99916.3 and Cytochrome P450 Family 4 Subfamily F Member 8 (CYP4F8).
Upon further data analysis, it was determined that TAF5L,
CYP4F3, LRP5L and AL022324.3 belong to both TNBC and
HER2 positive subtypes while, Z99916.3 and CYP4F8 were
just from HER2 positive subtype. Moreover, there were no
common target genes from non‐TNBC subtype of BC in this
particular dataset. Pathway analysis performed for ascertaining
the roles of these target genes in breast cancer indicated that
they regulate classic biological pathways which are crucial in
triggering breast cancer. They regulate metabolic and signalling
pathways, respectively. A brief illustration of this analysis is
provided in the Figure 7.
According to studies, TAF5L which regulates basal transcription, and helps in transcription initiation by regulating
transcription factors activity, is found to participate in PEDF‐
induced signalling and the GPCR pathway [38]. PEDF in the
normal state plays a potential role in tumour inhibition by its
anti‐angiogenic function [41]. The down regulation of PEDF
was observed overall in cancer, as its anti‐tumour activity may
diminish during tumour proliferation. Different studies have
also reported lower levels of PEDF in breast tumours, as it
plays an inhibiting role in tumour angiogenesis and controls
cellular differentiation [41, 42]. The GPCR pathway is
comprised of G‐protein coupled receptors which are transmembrane receptors, controlling signal transduction pathways
[43]. Cancer studies have found that GPCR plays a significant
role in oestrogen‐negative (ER negative) breast cancers [44].
The mechanism of GPCR involved in this cancer is the indirect
activation of epidermal growth factor receptor (EGFR), by the
release of epidermal growth factor (EGF) ligands from the
surface which activates the intracellular signalling pathways
[44]. Such an activated mechanism may result in increased
proliferation and tumour cell progression [45].
LRP5L was analysed through different studies to participate in the Wnt signalling pathway. It functions in Wnt‐protein
binding and Wnt‐activated receptor activity. It has a major role
in carcinogenesis and tumour progression [46, 47].
The target genes CYP4F3 and CYP4F8 were found to
regulate fatty acids/lipid metabolism [48]. The metabolic
reprogramming resulted due to gene mutations and epigenetic
changes during cellular transformation, plays a key role in
tumour cell development and progression. Proliferation and
metastasis are preserved in cancer cells by enhancing the aerobic glycolysis and fatty acid synthesis [49–51].
The list of mRNAs identified in our study was also validated by TCGA and GEPIA breast cancer cohort data. The
mRNA targets TAF5L and LRP5L were identified from
TCGA data, their mean expression in tumour and normal cells,
log2FC and p‐value is provided in Table 1. Also, the breast
cancer cohort data from GEPIA web‐based database and tool
was analysed to identify target mRNAs. CYP4R3, TAF5L and
LRP5L were retrieved (Table 1).
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F I G U R E 8 Brief Description of Targets and their Pathways. Blue coloured boxes represent lncRNAs and grey coloured boxes represent their cis‐ and trans‐
regulating mRNA targets. Red coloured lines with heads represent targets and arrows represent their relevant signalling pathways. The oval pink coloured boxes
represent cellular mechanisms, regulated by these pathways. The dotted circle represents the target genes which are present in the HER2 positive subtype
whereas the red star represents target genes common in both TNBC and HER2 positive subtype. LRP5L regulates the Wnt signalling pathway by binding to the
Wnt ligand. This pathway has a crucial role in breast cancer. AL022324.3 and Z99916.3 were found to be breast cancer targets, but their pathways are not
annotated yet. CYP4F3 and CYP4F8 genes regulate arachidonic acid (AA) metabolism and transform arachidonic acids to epoxyeicosatrienoic acid (EETs)
which are involved in angiogenesis and contribute to the tumour progression. TAF5L regulates pigment epithelium‐derived factor (PEDF) induced signalling
and the G‐protein coupled receptor (GPCR) pathway which are also the major contributors to the breast cancer pathways

TABLE 1

TCGA and GEPIA results: The list of Target mRNAs identified from TCGA and GEPIA data
mRNAs

Mean Expression in tumour

Mean Expression in Normal

log2FC

p‐value

1

TAF5L

2540.679

1697.212

0.43842

5.70E‐14

2

LRP5L

238.1071

200.7965

0.177151

0.115538

1

CYP4F3

0.100

0.090

0.013

7.16e‐6

2

TAF5L

16.381

12.300

0.386

7.34e‐25

3

LRP5L

2.740

6.520

−1.008

3.83e‐70

Sr. No
TCGA results

GEPIA results

Abbreviations: CYP4F3, Cytochrome P450 Family 4 Subfamily F Member 3; LRP5L, LDL Receptor Related Protein 5 Like; TAF5L, TATA‐Box Binding Protein Associated Factor 5
Like.

Thus, pathway analysis suggests that the signalling and
metabolic pathways identified play a vital role in breast cancer
regulation. Further investigation of these pathways could help
in breast cancer therapy.
The DEGs obtained from the analysis performed for
validation were further analysed for retrieving target mRNA
genes obtained from our study and it was observed that
GSE22820 includes TAF5L and CYP4F3 while GSE26910
involves AL022324.4, a contig sequence from one of the target
genes AL022324.3 among significantly differentially expressed
genes of breast cancer.
The WGCNA analysis was also performed for both
mRNA and lncRNA datasets to analyse the presence of
biomarker genes in our research. The subsets of common
genes from DEG analysis and WGCNA were observed among
all datasets;but specifically, the biomarker genes from our study
were not discovered from the results of WGCNA analysis.

4 | DISCUSSION
Both coding and non‐coding RNAs have been demonstrated
as the key regulators with various biological functions. 90% of
the human genome is transcribed into non‐coding RNAs and
also play an important role in the development and progression
of various types of cancers [52]. Breast cancer is one of the
lethal types of cancer and is largely regulated by lncRNAs and
mRNA [53, 54]. The aim of this study was to determine
candidate biomarker genes and potential therapeutic targets
that could aid in breast cancer therapy in the future. This study
was conducted on breast cancer data of lncRNA and mRNA
from two different platforms, that is microarray and RNA‐Seq.
The objective of the study was to observe the differential
expression patterns, co‐expression networks and pathway
analysis of both differentially expressed and co‐expressed
genes identified in breast cancer. The methodology used for
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this analysis includes microarray analysis, RNA‐Seq analysis,
DE analysis, co‐expression network analysis (WGCNA) and
integrative analysis of lncRNAs along with their cis‐ and trans‐
regulating target genes, which were integrated with identified
mRNA genes and their pathway analysis. Three common
lncRNAs were identified to be significantly differentially
expressed and co‐expressed with the breast cancer genes,
which include RP11‐108F13.2, RPL23AP2 and AL022324.2.
The RP11‐108F13.2 which was reported to be an lncRNA [55]
targets the mRNA gene, TAF5L. Through further analysis
processed pseudogene of ribosomal protein L23a (RPL23AP2)
was identified and its targets were CYP4F3, CYP4F8. Another
processed pseudogene AL022324.2 obtained from results targets LRP5L, AL022324.3 and Z99916.3, respectively. The
targets such as TAF5L, CYP4F3, LRP5L and AL022324.3
were common in both TNBC and HER2 positive subtypes,
while the remaining two that is Z99916.3 and CYP4F8 were
identified in HER2 positive subtype only and no significant
DE lncRNA or mRNA targets were observed in non‐TNBC
subtype.
The functional or molecular annotation of lncRNAs
identified in this study was very limited or not reported and
was determined only in some genomic databases being reported only as lncRNAs or pseudogenes with incomplete
annotation. There is still a gap in the molecular and functional
annotation of the lncRNAs which is required to be filled for
better and improved understanding of functional properties
and regulatory roles of lncRNAs in normal and diseased states,
particularly in cancers. Aberrantly expressed mRNA genes
were further examined through functional annotation and
pathway analysis. They were identified to be involved in
different biological processes such as metabolic and signalling
pathways. All these pathways were determined as the major
contributors in cancer progression and metastasis.
TAF5L gene was discovered through GO annotations to
regulate basal transcription, and helps in transcription initiation
by regulating promoter recognition and transcription factor
activity and also acts in histone acetyltransferase activity [56]. It
encodes for a protein which is the member of WD‐repeat of
the TAF5 family of proteins. The encoded protein belongs to
the PCAF histone acetylase complex [56] and comprises 20
different types of (TAF) polypeptide units and regulates cell
cycle progression, transcription, and cellular differentiation
[56]. A study has reported that PCAF is responsible for the
dysregulation of phosphatase and tensin homologue deleted on
chromosome 10 (PTEN) protein, which results in the tumour
progression in breast, lung, prostate and brain as PTEN is the
tumour suppressor gene [57]. According to a study, TAF5L
was reported as a biomarker in breast cancer [58]. It regulates
the PEDF‐induced signalling and GPCR pathways [38].
PEDF‐induced signalling plays a potential role in tumour inhibition and regulates anti‐angiogenesis [41]. The GPCR
pathway regulates signal transduction and activates EGFR
indirectly in cancer resulting in tumour progression and proliferation. Its role was also reported in ER‐negative breast
cancer [43, 44]. The overexpression of TAF5L was reported in
a study [58], which further affirms the upregulation of TAF5L
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as determined in our study. The upregulation TAF5L in breast
cancer is also validated from the results of TCGA and GEPIA
analysis with the positive Log2FC values which are provided in
supplementary file 12. These results support the identification
of TAF5L in this study and suggest that this gene could be
used as a potential biomarker in breast cancer diagnosis and
therapy.
The genes CYP4F3 and CYP4F8 encode for proteins
which belong to the super family of cytochrome P450 enzymes
[48], regulating several important biological processes,
including cholesterol, lipids and steroids synthesis and metabolism [48]. Over expression of CYP4F3 and CYP4F8 was
reported in several studies to regulate tumour progression and
proliferation in various types of cancers such as breast and
prostate cancer [59, 60]. They also regulate arachidonic acid
(AA) metabolism [48]. It was determined that the metabolic
reprogramming resulted due to gene mutations and epigenetic
changes during cellular transformation plays a key role in
tumour cell development and progression [61]. Cancerous cells
maintain their proliferation and other metastasis activities by
enhancing the aerobic glycolysis and fatty acid synthesis
[49–51]. Based on these findings, the upregulation of CYP4F3
and CYP4F8 in breast cancer can be confirmed along with
their role in tumour progression as their overexpression was
also identified in our study.
The role of LRP5L was reported to regulate Wnt protein
binding and to activate its receptors. It regulates the Wnt signalling pathway [62]. This pathway is the key regulator of
various cellular processes such as cell differentiation, cell fate,
proliferation and stem cell pluripotency. It consists of canonical and non‐canonical pathways, which regulate the gene
transcription and cytoskeleton of the cell. Aberrant expression
of Wnt signalling pathway was determined in various types of
cancers, including a lethal subtype of breast cancer known as
triple‐negative breast cancer (TNBC) [46]. Moreover, the
dysregulation of canonical pathways was observed in breast
cancer [47].
AL022324.3 and Z99916.3 were reported as clone‐based
genes acting as lncRNAs in the Ensemble genome database
[63]. Their molecular and functional annotations are not reported yet.
This analysis showed that aberrantly expressed lncRNAs
and their target mRNAs played important regulatory roles in
the biological pathways which lead to cancer upon deregulation. They were significantly differentially expressed and co‐
expressed in breast cancer pathways and were also identified
as the key regulators in breast cancer progression and metastasis. These integrated lncRNAs‐mRNAs on further investigation and analysis can be used as the potential biomarkers and
therapeutic targets for breast cancer in future.
For evaluation of the significant DEGs and confirmation
of their roles in BC, two mRNA and two lncRNA datasets
from the microarray platform were analysed. The mRNA data
of BC provided TAF5L, CYP4F3 and also involves
AL022324.4, a contig sequence from one of the target genes
AL022324.3 among significantly differentially expressed genes
which were also reported in this research as biomarker target
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mRNAs. The lncRNA datasets along with other DEGs provided the lncRNAs located nearest to those 3 biomarker long
non‐coding RNAs retrieved in this study. The exact locations
of the biomarker lncRNAs were not observed in these datasets,
which might be due to the fact that lncRNA dataset GSE80266
analysed in our study comprised novel lncRNAs with generalised BC samples without any specific conditions. Moreover, it
was re‐annotated on the basis of highest sequence score.
Furthermore, validation of the gene annotation retrieved from
the results of analysed datasets was also performed through
TCGA. The TCGA results support findings of the current
study. Furthermore, annotations for one of the datasets used
for validation GSE113851 were provided already and the other
dataset GSE119233 was from Basal‐like Breast Cancer, while
this study was focussed on the generalized BC dataset.
The overall analysis supports the results of our research
that target mRNAs can serve as potential biomarkers along
with the lncRNAs, which are discovered as novel biomarkers
and can serve as therapeutic targets in breast cancer.

5 | CONCLUSION
This study demonstrates that significantly differentially
expressed and co‐expressed genes can be used as potential
biomarkers and therapeutic targets as they are important regulators of cancer pathways. Advancements in complete molecular and functional annotation of lncRNAs are required.
Further progress in lncRNA‐mRNA interactions could be
explored through molecular analysis and qRT‐PCR. This
therapeutic discovery can be enhanced by identifying candidate
biomarkers that can be targeted in cancer therapy.
OR CID
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